伏硫西汀与文拉法辛治疗抑郁症的临床疗效观察

Observation of the clinical efficacy of vortioxetine and venlafaxine in the treatment of depression

目的研究伏硫西汀与文拉法辛治疗抑郁症的临床疗效和安全性。方法60例抑郁症患者,随机分为科研组和参照组,每组30例。参照组患者口服盐酸文拉法辛缓释片治疗,科研组患者口服氢溴酸伏硫西汀片。比较两组患者用药前后生活质量、抑郁评分、睡眠质量以及临床疗效、不良反应发生情况。结果用药后,科研组患者躯体功能、心理功能、社会功能及物质生活评分分别为(92.41±9.39)、(89.57±9.37)、(90.28±9.45)、(91.59±9.32)分,均高于参照组的(85.59±9.16)、(82.59±9.24)、(83.57±9.34)、(86.27±9.25)分,差异均具有统计学意义(P<0.05)。科研组用药1、2、4、6周后的抑郁评分分别为(17.34±1.53)、(14.23±2.14)、(10.15±4.05)、(6.05±2.12)分,均低于参照组的(19.25±1.25)、(16.23±2.02)、(12.28±4.12)、(9.83±3.14)分,差异均具有统计学意义(P<0.05)。科研组用药1、2、4、6周后的睡眠质量评分分别为(15.43±1.07)、(11.28±0.65)、(9.56±0.51)、(4.38±0.29)分,均低于参照组的(17.35±1.12)、(14.34±0.72)、(10.23±0.64)、(6.27±0.34)分,差异均具有统计学意义(P<0.05)。科研组治疗总有效率96.67%高于参照组的80.00%,差异具有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论与文拉法辛比较,伏硫西汀治疗抑郁症能提高疗效、改善患者生活质量及睡眠质量,可稳定病情,值得推广应用。

Objective To study the cclinical efficacy of vortioxetine and venlafaxine in the treatment of depression.Methods A total of 60 patients with depression were randomly divided into research group and reference group,with 30 cases in each group.Patients in the reference group were treated with venlafaxine hydrochloride sustained release tablets,while patients in the research group were treated with votioxetine hydrobromide tablets.The quality of life,depression sore and sleep quality before and after medication,clinical efficacy,and occurrence of adverse reactions were compared between the two groups.Results After medication,the physical function,psychological function,social function and material life score of the research group were(92.41±9.39),(89.57±9.37),(90.28±9.45)and(91.59±9.32)points,which were all higher than(85.59±9.16),(82.59±9.24),(83.57±9.34)and(86.27±9.25)points of the reference group,and the difference was statistically significant(P<0.05).After 1,2,4 and 6 weeks of medication,the depression score of the research group were(17.34±1.53),(14.23±2.14),(10.15±4.05)and(6.05±2.12)points,which were lower than(19.25±1.25),(16.23±2.02),(12.28±4.12)and(9.83±3.14)points of the reference group,and the difference was statistically significant(P<0.05).After 1,2,4 and 6 weeks of medication,the depression score of the research group were(15.43±1.07),(11.28±0.65),(9.56±0.51)and(4.38±0.29)points,which were lower than(17.35±1.12),(14.34±0.72),(10.23±0.64)and(6.27±0.34)points of the reference group,and the difference was statistically significant(P<0.05).The total effective rate 96.67%of the research group was higher than 80.00%of the reference group,and the difference was statistically significant(P<0.05).There was no statistically significant difference in incidence of adverse reactions between the two groups(P>0.05).Conclusion Compared with venlafaxine,vothiaxetine can improve the efficacy in the treatment of depression,improve the quality of life and sleep quality of the patients,and stabilize the condition,which is worthy of promotion and application.